Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes

BACKGROUND: Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after F...

Descripción completa

Detalles Bibliográficos
Autores principales: Koliani-Pace, Jenna L, Singh, Siddharth, Luo, Michelle, Hirten, Robert, Aniwan, Satimai, Kochhar, Gursimran, Chang, Shannon, Lukin, Dana, Gao, Youran, Bohm, Matthew, Swaminath, Arun, Gupta, Nitin, Shmidt, Eugenia, Meserve, Joseph, Winters, Adam, Chablaney, Shreya, Faleck, David M, Yang, Jiao, Huang, Zhongwen, Boland, Brigid S, Shashi, Preeti, Weiss, Aaron, Hudesman, David, Varma, Sashidhar, Fischer, Monika, Sultan, Keith, Shen, Bo, Kane, Sunanda, Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frederic, Sandborn, William J, Lasch, Karen, Siegel, Corey A, Dulai, Parambir S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799947/
https://www.ncbi.nlm.nih.gov/pubmed/31050734
http://dx.doi.org/10.1093/ibd/izz071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799947/
https://www.ncbi.nlm.nih.gov/pubmed/31050734
http://dx.doi.org/10.1093/ibd/izz071

Ejemplares similares